Saved report copy
Recorded
Amgen combo cuts death risk by 58% in aggressive lung cancer
Amgen presented full late-stage trial results at the European Society for Medical Oncology Congress showing that adding its immunotherapy Imdelltra to AstraZeneca's Imfinzi cut the risk of death by 58% in patients with extensive-stage small cell lung cancer. Median overall survival was 21.1 months with the combination versus 12.7 months with Imfinzi alone, and nearly 80% of combo patients were alive at one year versus 53%. The fast-growing cancer accounts for an estimated 60% to 70% of roughly 31,000 new U.S. small cell lung cancer cases each year, and the results could position Imdelltra as an earlier treatment option.